52 results about "SMAD" patented technology

The application discloses a use of a solute carrier family 25A33 gene in preparation of a medicament for treating presbycusis, and the use is achieved by enhancing SLC25A33 expression on an endolymphatic vascular stripe, by maintaining mitochondrial function stability of pericyte cells around the vascular stripe, by reducing active oxygen free radical (ROS) generation, and by blocking TGFbeta / SMAD pathway-mediated pericyte differentiation, so as to protect the integrity of the blood labyrinth barrier. Animal experiments show that overexpression of SLC25A33 can significantly reduce the hearing threshold of a presbycusis model mouse, protect the structure of the blood labyrinth barrier, and improve the expression of tight junction proteins, and the SLC25A33 gene has the potential to treat presbycusis.

The invention discloses an AI intervention analysis method for diabetic renal interstitial fibrosis, and relates to the technical field of biologication.The method comprises the following specific steps of sample collection and multi-omics data acquisition, specifically, kidney tissue samples of diabetic renal interstitial fibrosis patients before and after the diabetic renal interstitial fibrosis patients use glucose kidney health intervention and kidney tissue samples of healthy contrasts are collected; respectively acquiring epigenetic data and single-cell gene expression data, preprocessing, and integrating to construct a comprehensive data set; by combining the AI technology and the high-throughput epigenetic detection technology, the epigenetic modification change on a TGF-beta1 / Smads signal path in the process of intervening diabetic renal interstitial fibrosis by the Sushenkang can be deeply analyzed; a brand-new perspective is provided for understanding the occurrence mechanism of the diabetic renal interstitial fibrosis disease and the drug action mechanism of the TGF-beta1 / Smads pathway, epigenetic data is deeply mined through AI, and the specific mechanism of the TGF-beta1 / Smads pathway related gene expression affected by the TGF-beta1 / Smads pathway through epigenetic regulation is shown.

This invention discloses a sophoridine tricyclic derivative or its pharmaceutical salt, with the following general structural formula: R1 is selected from hydrogen, C1-C20 straight-chain alkyl, and C1-C20 branched alkyl. In vitro experiments have verified that the sophoridine tricyclic derivative can inhibit TGF-β-induced activation of hepatic stellate cells, improve CCl4- and bile duct ligation-induced liver injury and liver fibrosis in mice, inhibit TGF-β / Smads signaling pathway activation, and also inhibit diethylnitrosamine-induced primary liver cancer in mice. Therefore, this invention provides new evidence for the treatment, alleviation, or improvement of liver fibrosis or primary liver cancer using sophoridine tricyclic derivatives.

The present invention is based, in part, on cancer vaccine compositions that comprise PTEN- and p53-deficient cancer cells with activated TGFβ-Smad / p63 signaling pathway, and methods for using same to prevent and / or treat cancer.

The invention discloses a high-efficiency targeted anti-hepatic fibrosis oral nano drug delivery system and a preparation method thereof. According to the system, a sesquiterpene lactone component, namely lettuce lactone (LC), in Xinjiang traditional liver protection medicinal material cichorium glandulosum is used as a medicine core, and although the lettuce lactone has a good anti-fibrosis effect, the lettuce lactone (LC) has the problems of poor water solubility, high first-pass metabolism and the like. Therefore, 18 beta-glycyrrhetinic acid modified silicon-based hybrid micelles (LC-FS-G) are studied and constructed, the liver targeting property of glycyrrhetinic acid and a silicon-based cross-linked structure are utilized to enhance the stability, and drug release is responded in a glutathione (GSH) high expression environment by virtue of a disulfide bond. The particle size of the obtained micelle is uniform (27.83 nm), the encapsulation efficiency reaches 95.05%, and the drug loading rate is 10.62%. The system is slowly released in gastric juice (48h release lt); 50%), and the gt can be quickly released in a high GSH environment (36h release gt; 87%), and the liver fibrosis process can be reversed by regulating and controlling a TGF-beta / Smad pathway. According to the strategy, physicochemical and metabolic restrictions of LC are overcome, and a new way with high efficiency and low toxicity is provided for oral nano targeted therapy of hepatic fibrosis.

The invention discloses an application of a POSTN + fibroblast subgroup in screening and preparing a medicine for improving immune checkpoint blocking treatment drug resistance of a patient with head and neck squamous cell carcinoma. The action mechanism of small extracellular vesicles secreted by POSTN < + > fibroblasts in head and neck squamous cell carcinoma is studied, two fibroblast subtypes of POSTN <-> and POSTN < + > are identified through single-cell RNA sequencing, and the POSTN < + > subtype highly expresses FAP and other markers and is related to immune checkpoint blocking treatment drug resistance. Research finds that POSTN is enriched on the surface of sEVs secreted by POSTN + fibroblasts, and macrophages can be driven to be polarized to an M2 type by activating a BMP4 / BMPR2 / Smad signal channel. High expression of POSTN and FAP indicates that ICB treatment response of a patient is poor, and POSTN and FAP can be used as predictive biomarkers. The pathway can be blocked by down-regulating the POSTN, the ICB curative effect is improved, and a new target and a new strategy are provided for treatment of head and neck squamous cell carcinoma.

The invention discloses an application of a solute carrier family 25A33 gene in preparation of a medicine for treating senile deafness, which is characterized in that SLC25A33 expression on inner ear vascular lines is enhanced, the mitochondrial function stability of vascular periripple cells is maintained, the production of reactive oxygen species (ROS) is reduced, and pericyte differentiation mediated by a TGF (Transforming Growth Factor) beta / SMAD pathway is blocked, so that the senile deafness is inhibited, and the senile deafness is inhibited. Therefore, the integrity of the blood lost barrier is protected. Animal experiments show that overexpression of the SLC25A33 can significantly reduce the hearing threshold of an age-related deafness model mouse, protect the structure of a blood labyrinth barrier and improve the expression of tight junction protein, and the SLC25A33 gene has the potential of treating age-related deafness.

The invention belongs to the cross technical field of regenerative medicine and traditional Chinese medicine, and discloses a composition for treating premature ovarian failure and a preparation method and application thereof. The composition comprises adult stem cells, traditional Chinese medicine active components consisting of astragaloside and salvianolic acid B in a molar ratio of (1: 1)-(4: 1) and a biodegradable slow-release carrier, and double intervention of'cell repair-microenvironment regulation and control 'is realized through a synergistic strategy of'pretreatment of stem cells by traditional Chinese medicines and targeted slow-release delivery'. Experiments prove that the composition can enable the estrus cycle recovery rate of premature ovarian failure model animals to reach 70%-90% and the number of follicles to be increased by 6-8 times, is obviously superior to the existing single therapy, has a clear mechanism (activating a PI3K / Akt pathway and inhibiting a TGF-beta1 / Smad pathway), and has outstanding clinical transformation value.

The invention belongs to the field of biological medicines, and particularly discloses application of a beta-carbon alkali alkaloid derivative, i.e., senecionone, in preparation of an anti-pulmonary fibrosis medicine, and a series of experiments prove that the senecionone can regulate and control a TGF-beta / SMAD signal channel by inhibiting phosphorylation of SMAD < 2 / 3 >, so that fibroblasts are inhibited from being converted into myofibroblasts, and the anti-pulmonary fibrosis effect is achieved. The generation of extracellular matrix protein COL1 and the like is reduced, so that the pulmonary fibrosis is relieved.

The invention belongs to the technical field of traditional Chinese medicine and application thereof, and particularly relates to application of silybum marianum alcohol extract in preparation of medicine for treating deep II-degree burns and scalds. When the silybum marianum alcohol extract is applied to preparation of the medicine for treating deep II-degree burns and scalds, oxidative stress injury is improved by activating an Nrf2 / HO-1 pathway, and fibrosis is inhibited by regulating a TGF-beta / Smad pathway so as to promote repair of the deep II-degree burns and scalds. According to the method, the yield of the silybum marianum alcohol extract is improved by optimizing the extraction conditions of the silybum marianum; it is clear that the silybum marianum alcohol extract has multiple mechanisms of resisting oxidation, inhibiting fibrosis and resisting inflammation, the silybum marianum alcohol extract has a remarkable promoting effect on treatment and repair of deep II-degree burns and scalds, and theoretical basis and experimental support are provided for silybum marianum serving as a potential treatment medicine for scar-free healing after deep II-degree scalds.

The invention discloses an application of butyric acid or a derivative thereof in preparation of a zearalenone reproductive toxicity resisting preparation. Also disclosed is an antitoxic feed composition comprising a specific base ration and a butyric acid derivative. In-vivo and in-vitro tests and molecular mechanism researches prove that butyric acid and derivatives thereof (such as tributyrin and sodium butyrate) can effectively relieve zearalenone (ZEN)-induced animal ovary injury. The action mechanism of the traditional Chinese medicine composition is that follicular atresia is reduced, the balance of reproductive hormones (such as GnRH, E2, AMH and P4) is recovered, and clinical symptoms caused by ZEN poisoning such as vulva swelling and the like are relieved by activating a BMPs / SMAD signal channel, especially up-regulating SMAD4 protein expression and inhibiting oxidative stress (ROS) and Caspase-3 mediated granular cell apoptosis.

Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclosure describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening.

The invention discloses a TGF-beta / Smad signal channel inhibitor. The TGF-beta / Smad signal channel inhibitor is prepared from the following components in parts by mass: 1000 parts of tea oil, 0.09 to 9.8 parts of bakuchiol and 0.01 to 0.2 part of acetyl hexapeptide-8, the invention also discloses a method for preparing the TGF-beta / Smad signal channel inhibitor as described above. The invention also discloses a cosmetic, which contains the TGF-beta / Smad signal channel inhibitor as an active component. The invention further discloses a method for evaluating the anti-aging effect of the cosmetic. According to the composition, by inhibiting abnormal activation of a TGF-beta / Smad signal channel, excessive deposition and crosslinking of an extracellular matrix are reduced, meanwhile, synthesis of collagen and elastin is promoted, aging characterization such as skin laxity and wrinkles is effectively improved, and deep repair and rejuvenation remodeling of skin aging damage are achieved.

The invention belongs to the technical field of medical chemistry, and particularly relates to a polycyclic polyketone derivative as well as a preparation method and application thereof in treating hepatic fibrosis. Six polycyclic polyketone compounds are obtained from a fungus M. arundinis HL1 separated from a marine sample in Huilaxian County, Guangdong Province, the series of compounds can significantly inhibit expression of FN, Collagen I, alpha-SMA and other fibrosis-related factors in hepatic stellate cells LX-2, and the compound 2 has a significant inhibition effect at a concentration of 40 [mu] mol / L and has no significant toxicity. And the compound 2 reduces the p-Smad2 / 3 level through dose dependence, does not influence the total Smad2 / 3 level, and plays an anti-fibrosis role by inhibiting a TGF-beta / Smad signal channel. The series of compounds, especially the compound 2, are expected to become anti-hepatic fibrosis candidate drugs, and provide a brand new chemical skeleton for research and development of low-toxicity and high-efficiency anti-hepatic fibrosis drugs.

The method for producing a cell aggregate including glial progenitor cells according to the present invention comprises:(1) a step of subjecting pluripotent stem cells to suspension culture in an embryoid-body-forming culture medium containing one or more SMAD signaling inhibitors and one or more Wnt signaling activators in the absence of feeder cells for 5 days to 10 days, to form a cell aggregate;(2) a step of subjecting the cell aggregate obtained in (1) to suspension culture in an embryoid-body-forming culture medium containing retinoic acid;(3) a step of subjecting the cell aggregate obtained in (2) to suspension culture in an embryoid-body-forming culture medium or neuron-and-glia-proliferating culture medium containing retinoic acid and one or more SHH signaling activators; and(4) a step of subjecting the cell aggregate obtained in (3) to suspension culture in a neuron-and-glia-proliferating culture medium containing no retinoic acid and one or more SHH signaling activators.

Provided are: an improved culture medium composition which can be used for culturing pluripotent stem cells of mammals, preferably for establishing and maintaining pluripotent stem cells of mammals useful for producing cultured meat for cattle, pigs, or the like; and a culture method using the culture medium composition. The culture method according to the present invention comprises a step of culturing pluripotent stem cells of mammals in a culture medium composition, the culture medium composition being a culture medium composition for culturing pluripotent stem cells of mammals, the culture medium composition being a serum-free culture medium containing (1) a CDK8 / 19 inhibitor, (2) a ROCK inhibitor, (3) a SMAD activator, and (4) a STAT3 activator.

This invention belongs to the field of medicine, specifically disclosing a drug-loaded biomimetic nanodecoy based on genetic engineering, its preparation method, and its application. The drug-loaded biomimetic nanodecoy of this invention comprises CCR2-overexpressing nanovesicles, and the hydrophobic regions of the nanovesicles are loaded with curcumin. This invention also provides a method for preparing the drug-loaded biomimetic nanodecoy based on genetic engineering and its application. The overexpressed CCR2 is used to adsorb excess CCL2 to inhibit the binding of macrophages to CCL2, preventing macrophage chemotaxis and subsequent TGF-β production. This inhibits the activation of hepatic stellate cells by removing pro-fibrotic mediators upstream; simultaneously, curcumin is released to block the downstream TGF-β / Smad signaling pathway, thereby inhibiting the activation of hepatic stellate cells.

The invention discloses an application of glutathione peroxidase 3 as a therapeutic target in preparation of a medicine for treating pulmonary fibrosis, and an application of a compound Ebselen in preparation of a medicine for treating pulmonary fibrosis. Through single cell and space transcriptomics analysis, it is found for the first time that expression of GPX3 in pulmonary fibrosis patients and model animal lung tissues is significantly reduced. In-vivo and in-vitro experiments prove that up-regulation of GPX3 expression can effectively inhibit fibroblast activation, migration, proliferation and oxidative stress and block a TGF-beta1 / Smad signal channel, so that collagen deposition and pulmonary fibrosis pathological change are relieved. Furthermore, a GPX3 simulant Ebselen is given by adopting an aerosol inhalation mode, is preferably loaded in liposome, and shows a remarkable anti-fibrosis effect in two mouse pulmonary fibrosis models induced by bleomycin and silicon dioxide. The invention provides a brand-new therapeutic target and a medicine scheme with clinical transformation potential for pulmonary fibrosis.

The invention discloses a hysteromyoma postoperative anti-adhesion absorbable film and a preparation method thereof, and belongs to the technical field of biomedical materials. The membrane is prepared from hydroformylated hyaluronic acid, catechol functionalized gelatin, a siTGF-beta1 / LMWC nano-composite and a siSmad3 / PEI nano-composite through a dynamic covalent cross-linking and gene sequential controlled release technology. A-HA and C-Gel are subjected to a Schiff base reaction to form a dynamic crosslinking matrix with self-healing, wet adhesion and controllable degradability; the siTGF-beta1 and the siSmad3 respectively target an upstream switch and a central hub of a TGF-beta1 / Smad pathway, and time sequence release is realized by means of the characteristic difference between the LMWC and the PEI. An in-vitro experiment proves that the inhibition rate gt of the membrane on a fibroblast fibrosis marker is gt; the effect can be maintained for 28 days, the biocompatibility is excellent, the clinical operation is convenient, the postoperative adhesion is prevented from the molecular source, the defects of single target spot and short effect in the prior art are overcome, and the clinical application value is great.

The invention relates to the technical field of biomedicine, in particular to a method for promoting formation of nerve fasciae and repair and regeneration after sciatic nerve defect by using small extracellular vesicles (hfNCSCs-sEVs) derived from hair follicle neural crest stem cells and application. According to the application disclosed by the invention, the effects of the hfNCSCs-sEVs on proliferation, migration, tube formation and barrier formation of nerve fascia cells in vitro are defined; the effect of hfNCSCs-sEVs on tissue regeneration and function recovery after rat sciatic nerve defect is defined, the hfNCSCs-sEVs inhibits expression of Smad7 in nerve tract membrane cells by transferring miR-21-5p, activates a TGF-beta / Smad signal channel, up-regulates expression of HAS2, promotes proliferation and migration of HAS2 and promotes expression of tight junction protein thereafter, and the hfNCSCs-sEVs can be used for treating rat sciatic nerve defect. And a new view angle and theoretical support are provided for repair and regeneration of sciatic nerve injury.

The invention relates to the technical field of TGF-beta regulating peptides, in particular to a TGF-beta regulating peptide as well as a composition, a product and application thereof. The amino acid sequence of the TGF-beta regulating peptide disclosed by the invention comprises (a) any one of the amino acid sequences shown as SEQ ID NO. 1-SEQ ID NO. 20, (b) any one of the amino acid sequences shown as SEQ ID NO. (b) amino acid sequences which are obtained by modifying the N end and / or the C end of the TGF-beta regulating peptide limited by (a) and have the same or similar functions. The TGF-beta regulating peptide provided by the invention can effectively activate a TGF-beta / Smad signal channel, promote the synthesis of collagen and inhibit the generation of sebum, has the effects of resisting skin aging and regulating grease secretion, and has a wide application prospect in the fields of medicines, foods and cosmetics.

The invention discloses a radix ophiopogonis decoction anti-pulmonary fibrosis active component separated based on a centrifugation-membrane dialysis method and application of the radix ophiopogonis decoction anti-pulmonary fibrosis active component. Belongs to the field of ophiopogon root soup. The invention aims to solve the problem that the research on the ophiopogon root decoction mostly focuses on component analysis, pharmacological effect and the like in the prior art. The precipitation phase state, CP-I, CP-II and true solution phase state of the ophiopogon root decoction are successfully separated by adopting a centrifugation-membrane dialysis method. The results of qualitative and quantitative analysis of chemical components show that CP-I is closer to D, D, CP-I can more effectively improve PF symptoms compared with CP-II, and D, CP-I and CP-II do not cause damage to A549 cells and inhibit proliferation of the A549 cells induced by TGF-beta1 to different degrees. Compared with CP-II, the D and CP-I can more remarkably inhibit phosphorylation of protein Smad2 / 3, and the D, CP-I and CP-II can weaken the EMT of A549 cells induced by TGF-beta1 by blocking a TGF-beta1 / Smad pathway. CP-I is an effective phase state of the ophiopogon root decoction.

The invention relates to the field of medicines, in particular to application of FGF11 (fibroblast growth factor 11) in preparation of medicines for treating intrauterine adhesion. It is found for the first time that FGF11 preventive treatment can recover the damaged uterus form of an intrauterine adhesion rat, relieve the fibrosis level, promote proliferation of damaged endometrial epithelial cells and blood vessels and improve the pregnancy rate of an IUA rat. The mechanism may be that the damaged uterine fibrosis is inhibited through a TGF-beta1 / Smads signal channel, and the damaged endometrial function is recovered. Theoretical and experimental basis is provided for clinically applying FGF11 to treat intrauterine adhesion.

The invention provides application of irisin and resveratrol in preparation of a preparation for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of biological medicine. The invention finds that combined use of irisin and resveratrol shows a remarkable synergistic effect in the aspects of reducing the radiation-induced oxidative stress level and inflammatory response, and the effect is superior to that of single use of irisin and resveratrol. According to the combination scheme, the inflammation stage and the fibrosis stage of the radiation-induced lung injury are intervened at the same time, the inflammatory reaction is relieved, and meanwhile the fibrosis process is inhibited by adjusting a TGF-beta1 / Smad signal channel. Besides, irisin serving as an endogenous polypeptide and resveratrol serving as a natural product have good safety, so that the immunosuppression risk caused by a large dose of hormone can be avoided.

The invention discloses an anti-gastric cancer traditional Chinese medicine composition and a graded enzymolysis preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: astragalus membranaceus, codonopsis pilosula, rhizoma polygonati, oldenlandia diffusa, sculellaria barbata, radix actinidiae chinensis, pseudo-ginseng, poria cocos, semen coicis, liquorice and glossy privet fruit. The graded enzymolysis preparation method comprises the steps of medicinal material grading treatment, stepped enzymolysis purification and integrated freeze-drying forming. Experiments prove that astragalus membranaceus, codonopsis pilosula and rhizoma polygonati can significantly improve the levels of serum IL-2 and IFN-gamma, oldenlandia diffusa, sculellaria barbata and radix actinidiae chinensis can effectively inhibit VEGF gene expression, pseudo-ginseng, poria cocos and coix seeds enhance tumor metastasis resistance by adjusting a TGF-beta / Smad pathway, and the risk of drug-induced liver injury can be reduced by containing liquorice and glossy privet fruit, so that the drug-induced liver injury treatment effect is improved, and the drug-induced liver injury treatment effect is improved. The stomach cancer is effectively treated.

The invention provides application of an LRG1 inhibitor or a miR-145-5p nano-complex in preparation of a medicine for preventing and / or treating prostatitis, and belongs to the technical field of biological medicine manufacturing. The invention discloses application of an LRG1 inhibitor in preparation of a medicine for preventing and / or treating prostatitis. In order to further improve the stability and the delivery efficiency of the miR-145-5p in vivo when the miR-145-5p is used as an LRG1 inhibitor, the invention provides a miR-145-5p nano-composite which is a polymer nano-particle loaded with the miR-145-5p. According to the invention, through targeted down-regulation of LRG1 and regulation and control of a TGF-beta / Smad signal channel, polarization of macrophages from M1 to M2 is remodeled, and oxidative stress of prostate tissues is synchronously relieved, so that mandatory treatment of prostatitis is realized.

The invention discloses application of indole-3-formaldehyde in preparation of a product for treating type-2 diabetes mellitus complicated with metabolic dysfunction related steatohepatitis, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, a T2DM-MASH mouse model is successfully established, not only is the effect of the type 2 diabetes mellitus in acceleration of MASLD fibrosis progress proved, but also a dual treatment mechanism of indole-3-formaldehyde (3-IAld) on the type 2 diabetes mellitus complicated with metabolic dysfunction related steatohepatitis is clarified for the first time; meanwhile, SIRT1 is activated to inhibit a TGF-beta / SMAD signal channel, so that the effect of treating type-2 diabetes mellitus complicated with metabolic dysfunction related steatohepatitis is achieved. These findings provide new therapeutic targets and strategies for the treatment of type-2 diabetes mellitus complicated with metabolic dysfunction related steatohepatitis.

The invention relates to a preparation method and application of serum exosome miR-98-5p of an asthma patient, and belongs to the technical field of biological medicine and molecular biology. The preparation method of the serum exosome miR-98-5p of the asthma patient comprises the following steps: S1, collecting the serum of the asthma patient, heating to quickly melt a sample, then performing centrifugal treatment, taking supernate, filtering by a filter membrane, and collecting filtrate; s2, the filtrate is subjected to centrifugal treatment, supernate is removed, and an exosome crude extract is obtained; s3, the exosome crude extract is subjected to centrifugal treatment after being resuspended, supernate is removed, resuspension is conducted, and the serum exosome of the asthma patient is obtained. According to the present invention, BEAS-2B cells are treated by using the serum exosome of an asthma patient, a miR-22-3p mediated TGF-beta / SMAD pathway is down-regulated to participate in cell epithelial-mesenchymal transition, and proliferation and migration of lung epithelial cells BEAS-2B are promoted;

The present application relates to the technical field of biological medicine, and particularly relates to a nitrile glycoside compound, a preparation method thereof and application of the nitrile glycoside compound in preventing and / or treating kidney disease. A structural formula of the nitrile glycoside compound is shown as follows: wherein R is selected from hydrogen, substituted rhamnose, glucose, substituted glucose, mannose and substituted mannose; the substituents on the substituted rhamnose, the substituted glucose and the substituted mannose are independently selected from formyl, acetyl, propionyl, butyryl, C1-C6 alkyl, C1-C6 alkoxy, halogen, sulfonic acid group or amino; and the substituents on the substituted rhamnose, the substituted glucose and the substituted mannose are located at 2 and 4 positions of a monosaccharide cyclic structure. The present application shows that the nitrile glycoside compound can relieve diabetic nephropathy by driving metabolic reprogramming and a PFKFB3 / TGF-beta / Smads pathway, and has a good treatment effect.